Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

RAS(ON) Inhibitors Revolution Medicines develops oral targeted therapies that bind active, GTP-loaded RAS proteins. Its portfolio covers multiple RAS mutations and combination strategies across pancreatic and lung cancers. Daraxonrasib Daraxonrasib is a multi-selective RAS(ON) inhibitor and the company's lead late-stage asset. It has...

Recent company news

RVMDRevolution Medicines2026-08-10 10:01 EST

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

RVMDRevolution Medicines2026-07-29 20:05 EST

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

RVMDRevolution Medicines2026-07-22 20:05 EST

Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

RVMDRevolution Medicines2026-07-07 13:24 EST

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

Stock data

Close: 209.46 USD
Market cap: 32.17B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

Related news

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Revolution Medicines